| Victoria Vest, CNM | |
|
96 Campus Drive, Third Floor, Scarborough, ME 04074 | |
| (207) 885-8400 | |
| (207) 885-8498 |
| Full Name | Victoria Vest |
|---|---|
| Gender | Female |
| Speciality | Advanced Practice Midwife |
| Location | 96 Campus Drive, Scarborough, Maine |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1982670204 | NPI | - | NPPES |
| 466401900 | Medicaid | DC | |
| 010189055 | Medicaid | DC |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367A00000X | Advanced Practice Midwife | AM092001 (Maine) | Primary |
| 367A00000X | Advanced Practice Midwife | RN64841 (District Of Columbia) | Secondary |
| Mailing Address | Practice Location Address |
|---|---|
| Victoria Vest, CNM 96 Campus Drive, Third Floor, Scarborough, ME 04074 Ph: (207) 885-8400 | Victoria Vest, CNM 96 Campus Drive, Third Floor, Scarborough, ME 04074 Ph: (207) 885-8400 |
News Archive
Data from the CREST (Carotid Revascularization Endarterectomy vs. Stenting Trial) study were published today in The New England Journal of Medicine. In this trial, stenting and surgery had similar initial safety and longer-term outcomes for symptomatic and asymptomatic men and women. Adverse event rates of death, stroke and heart attack were also similar for both therapies.
The American Physical Society agrees with President Obama's emphasis on science in his proposed Fiscal Year 2012 budget. His priorities keep the nation on a path of scientific advancement, technological innovation and economic growth.
The same gene that accounts for part of a genetic risk for developing alcoholism in a U.S. population is found in a Russian population, according to a published study by a Yale School of Medicine researcher.
Pro-Pharmaceuticals, Inc., a developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today announced that it has granted PROCAPS S.A. exclusive rights to market and sell DAVANAT® to treat cancer in Colombia, South America. Phase ll clinical trial results for late-stage colorectal cancer patients demonstrate that when DAVANAT® is co-administered with the chemotherapy drug 5-FU, survival increased by 46% over the best standard of care and reduced serious adverse events associated with chemotherapy.
Magnetic resonance imaging (MRI) enables radiologists to accurately identify tumors missed by mammography and ultrasound, according to a multicenter study comparing the three screening methods in women at high-risk for breast cancer.
› Verified 8 days ago
Linda Atherton Hackett, CNM Advanced Practice Midwife Medicare: Not Enrolled in Medicare Practice Location: 96 Campus Dr, 3rd Floor, Scarborough, ME 04074 Phone: 207-885-8400 Fax: 207-885-8498 |